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Objective: The prevalence of myopia is increasing around the world, stimulating interest in 2 
methods to slow its progression. The primary justification for slowing myopia progression is to 3 
reduce the risk of vision loss through sight-threatening ocular pathology in later life. The paper 4 
analyzes whether the potential benefits of slowing myopia progression by one diopter justify the 5 
potential risks associated with treatments.  6 
Methods: First, the known risks associated with various methods of myopia control are 7 
summarized, with emphasis on contact lens wear. Based on available data, the risk of visual 8 
impairment and predicted years of visual impairment are estimated for a range of incidence levels. 9 
Next, the increased risk of potentially sight threatening conditions associated with different levels 10 
of myopia are reviewed. Finally, a model of the risk of visual impairment as a function of myopia 11 
level is developed, and the years of visual impairment associated with various levels of myopia and 12 
the years of visual impairment that could be prevented with achievable levels of myopia control is 13 
estimated.  14 
Results: Assuming an incidence of microbial keratitis between 1 and 25 per 10,000 patient years 15 
and that 15% of cases result in vision loss, leads to the conclusion that between 38 and 945 16 
patients need to be exposed to five years of wear to produce 5 years of vison loss. Each 17 
additional diopter of myopia is associated with a 57%, 20%, 21%, and 30% increase in the risk 18 
of myopic maculopathy, open angle glaucoma, posterior subcapsular cataract, and retinal 19 
detachment, respectively. The predicted mean years of vi ual impairment ranges from 4.42 in a –20 
3 D myope to 9.56 in a –8 D myope and a one diopter reduction would lower these by 0.74 and 21 









number needed to treat to prevent 5 years of visual impairment is between 4.1 and 6.8 while 23 










There is compelling evidence that the prevalence of myopia is increasing around the world. The 26 
global prevalence is projected to reach 50% by the year 2050 in the absence of effective 27 
intervention measures.1 The rising prevalence of myopia is also accompanied by earlier onset, 28 
which in turn leads to an increased risk of high myopia.2-4 Increased prevalence of myopia, in 29 
particular high myopia, in turn is leading to increas d visual impairment due to conditions 30 
associated with myopia.5-7 Indeed, myopic maculopathy, also known as myopic macular 31 
degeneration, is an increasing cause of visual impair ent.6, 8 The onset of myopic maculopathy 32 
is earlier than other major causes of visual impairment, occurring as early as the fifth decade of 33 
life,9 so the years of impairment are commensurately greater than later onset conditions, 34 
including age-related macular degeneration (AMD).10, 11 In both Europe and China, visual 35 
impairment from myopic maculopathy is more common than visual loss from diabetic eye 36 
disease.12-14 37 
 38 
These factors have stimulated interest in methods t slow myopia progression, with a number of 39 
therapies, including topical atropine, spectacle lenses, dual-focus contact lenses, multifocal soft 40 
contact lenses, and overnight orthokeratology showing clinically meaningful slowing of 41 
progression.15-18 The preferred method varies with country and by profession.19, 20 Regulatory 42 
approval can also play a role, although the majority of myopia control in the US is performed 43 
off-label as only one device is approved for this indication. The influence of behavioral 44 
modifications, such as increased time outdoors and reduced screen time, on progression rate is 45 










There are, however, varying opinions regarding myopia control. Advocates for myopia control 48 
say that “it is unethical not to offer myopia control” and some clinical trials have moved children 49 
out of the placebo arm and into the treatment because of the significant treatment benefits.23, 24 In 50 
contrast, some professional organizations such as the College of Optometrists in the United 51 
Kingdom express caution, stating that there is “not enough evidence to support the widespread 52 
roll out of myopia control.”25 In addition, some clinicians feel that the increased potential risk of 53 
serious ocular infections argue against prescribing contact lenses to children. Other organizations 54 
are paying attention to issues related to myopia control. The American Academy of 55 
Ophthalmology, for example, has published two Ophthalmic Technology Assessments related to 56 
myopia control in recent years,26, 27 having previously reviewed the safety of one approach,28 and 57 
includes “Prevention of Myopia Progression” in its Refractive Errors & Refractive Surgery 58 
Preferred Practice Pattern.29 59 
 60 
In a thoughtful editorial, Modjtahedi and colleagues emphasize the need to increase awareness 61 
about the increasing prevalence of myopia.30 They state that “creating models to accurately 62 
stratify patient risk should be a significant focus for future research endeavors” and that “it is 63 
essential for ophthalmologists to work with optometrists, who are frontline providers, to 64 
determine a collaborative frame work and referral ptterns to prevent myopic progression, 65 
educate patients on the risks of myopia, and proactively address associated pathology to serve 66 
the best interest of our patients.” 67 
 68 
Methodological Considerations in Risk-Benefit Analysis of Myopia Treatment 69 
These varying perspectives point to the central question that this paper addresses; do the 70 









pharmaceutical options justify the potential risks associated with those treatments? The primary 72 
justification for reducing myopia progression is to reduce the risk of vision loss through sight-73 
threatening ocular pathology in later life. Therefo, myopia is being managed because it is a risk 74 
factor for visual impairment. The risk-benefit analysis of any treatment can be considered on a 75 
population or an individual basis. Not every patient with a risk factor for a condition will develop 76 
the condition, so a number of patients will be treated to avoid one adverse outcome, be it onset of 77 
disease or visual impairment. The parameter, number ne ded to treat (NNT), is widely used in 78 
health assessments, and is the reciprocal of the absolute risk reduction (ARR). For example, in 79 
the Ocular Hypertension Treatment Study (OHTS),31 the five-year cumulative probability of 80 
developing glaucoma was 9.5% and 4.4% in untreated nd treated patients, respectively. Thus, 81 
the ARR is 5.1% (= 9.5 – 4.4) and the NNT is 19.6 (= 1 ÷ 0.051). In other words, 20 patients 82 
need to be treated for 5 years in order to prevent one case of glaucoma. The ARR and NNT can 83 
be balanced by the corresponding parameters; the absolute risk increase (ARI), which is the risk 84 
associated with complications of the treatment and the number needed to harm (NNH), which is 85 
the number of patients who need to be treated in order to induce a single adverse event. NNH is 86 
the reciprocal of ARI.  87 
 88 
Slowing myopia progression by one diopter (D) offers the prospect of leaving a myope at –3 D 89 
with treatment rather than –4 D, or achieving a finl refraction of –7 D with treatment rather than 90 
–8 D. On the basis of existing data, both outcomes offer potential benefits but the ARR is much 91 
greater in high myopes due to the higher prevalence of myopia-related vision impairment (and 92 
the NNT lower) in higher myopes. While the NNT will be greater in lower myopes, they far 93 









ARR are a function of the effectiveness of a myopia intervention, irrespective of the treatment, 95 
and the level of myopia at the start of treatment. In contrast, the values of NNH and ARI relate to 96 
the specific method of treatment and are largely independent of the level of myopia. Therefore, 97 
the risk-benefit assessment of myopia treatment must consider all these elements, i.e., the 98 
effectiveness of an intervention in slowing down myopia progression, the risk of vision 99 
impairment associated with myopia, the level of myopia, and the treatment-modality specific 100 
risks. A final consideration is that complications of myopia treatment may occur many decades 101 
before any myopia-associated visual loss, so the duration in years of any treatment associated 102 
complications affecting vision may greatly exceed the duration of vision loss attributable to 103 
myopia later in life.  104 
 105 
In order to answer the central question of whether  benefits of active myopia control justify 106 
the risks, this review will first summarize the known risks associated with various methods of 107 
myopia control, with an emphasis on contact lens wear. Based on available data, the risk of 108 
visual impairment and predicted years of visual impairment are estimated for a range of 109 
incidence levels. Next, the increased risk of potentially sight threatening conditions associated 110 
with different levels of myopia is reviewed. Finally, a model of the risk of visual impairment as a 111 
function of myopia level and age is developed, and the years of visual impairment associated 112 
with various degrees of myopia and the years of visual impairment that could be prevented with 113 
achievable levels of myopia control is estimated. 114 
 115 
Risks and Side Effects of Myopia Control 116 
At the time of this review, there are three commonly used myopia control therapies—spectacles, 117 










Spectacles  120 
Myopia control with spectacles has a 60-year history, including bifocals,32-34 progressive 121 
addition lenses,35-37 and, most recently, novel optical designs.38 In the United States, children are 122 
prescribed polycarbonate spectacle lenses and the minimal physical risks associated with these 123 
devices are not increased by the incorporation of a multifocal correction or other designs. 124 
Spectacle wear is associated with bicycle crashes in children, although there is no association 125 
between myopia or habitual visual acuity and bicycle crashes.39 The study authors thus attribute 126 
the increased risk to a “decrement in the peripheral visual field, thus reducing rider awareness of 127 
oncoming vehicles and road obstacles.” Of course, corre ting myopia and eliminating blurred 128 
vision has its own benefits. Some spectacle based myopia treatments, incorporating positive 129 
dioptric power will be expected to have modest effects on peripheral vision and it is important 130 
that this be quantified.40 There is also evidence that in the elderly, multifocal and bifocal 131 
spectacles, can increase the risk of falls.41-43 Progressive addition lens and bifocal wearers are 132 
twice as likely to fall as non-multifocal wearers,43 although there is no evidence that the same 133 
risks apply in children, perhaps because they rarely w ar such lenses. 134 
 135 
Atropine  136 
Atropine is an antimuscarinic agent that causes pupil dilation and loss of accommodation, even 137 
in concentrations as low as 0.01%.24, 44 The associated symptoms of photophobia and near vision 138 
difficulties vary, as expected, with concentration. This can be mitigated by photochromic lenses, 139 
multifocals, or both. In the Atropine for the Treatment of Myopia 2 (ATOM2) study, among 140 
children receiving 0.5%, 0.1%, and 0.01% atropine, 70%, 61%, and 6%, requested combined 141 









vision photochromic spectacles.44 In the Low-Concentration Atropine for Myopia Progression 143 
(LAMP) Study, the need for photochromic or progressive addition lenses did not vary with 144 
atropine concentration among the over 400 children ra domized to 0.01%, 0.025%, 0.05% 145 
atropine or placebo.24 Between 30 and 40% children needed photochromic spe tacles in all 146 
groups including the placebo. Furthermore, four children needed progressive addition spectacles, 147 
including one in the placebo group. The most common ocular side effect in the aforementioned 148 
clinical trials was allergic conjunctivitis which occurred in 3 to 7% of children in each arm, 149 
including those receiving placebo in the LAMP Study, suggesting that the preservative or other 150 
excipient in the solution may be the causative agent. 151 
 152 
With any topically applied drug, there is a risk of systemic absorption. The systemic effects of 153 
atropine are well documented and include dryness of kin, mouth and throat due to decreased 154 
mucous membrane secretion, restlessness, irritability or delirium due to CNS stimulation, 155 
tachycardia, and flushed facial skin due to its non-selective antimuscarinic properties.45 In spite 156 
of atropine’s use in a large number of clinical trials for myopia control24, 44, 46 and for 157 
penalization therapy for amblyopia,47-50 involving hundreds of children there have been no 158 
reports of systemic adverse events related to topical atropine.  159 
  160 
The Ophthalmic Technology Assessment on Atropine for the Prevention of Myopia Progression 161 
in Children by the American Academy of Ophthalmology does not list any safety concerns.26 162 
The review does not discuss the risks associated with increase retinal light levels and AMD with 163 
atropine-induced mydriasis, but this remains a theoretical possibility, although the dilation with 164 









be offset by sunglasses. This theoretical risk is partly mitigated by the fact that myopia is a 166 
protective risk factor for AMD,51-53 possibly by the reduced light flux density that results from a 167 
longer eye.54 There are also potential concerns from premature presbyopia induced by prolonged 168 
partial cycloplegia, but we are only aware of anecdotal reports. A seven-year review of atropine 169 
in Taiwan, where atropine has been used for several d cades, did not include any data on side 170 
effects.55 This is clearly an area where further data are requi d. In summary, the risk of vision 171 
loss associated with topical atropine, particularly lower concentrations would appear to be very 172 
low, but the prescription of photochromic spectacles or soft contact lenses may be required at 173 
higher concentrations.  174 
 175 
Soft Contact Lenses 176 
The complications associated with soft contact lens wear have been well documented. Non-177 
infectious inflammatory events may involve the cornea, conjunctiva, and periorbital tissues. 178 
Those affecting the cornea are collectively termed corneal infiltrative events and include 179 
infiltrative keratitis, contact lens associated redeye, contact lens peripheral ulcers and occur at a 180 
rates between 300 and 400 per 10,000 patient years in dults.56-58 These are not considered to be 181 
sight-threatening and are managed by temporarily discontinuing contact lens wear, with the 182 
possible addition of a topical prophylactic antibiotic. Microbial keratitis is less common, with an 183 
incidence of around 20 per 10,000 patient years in adults wearing lenses on an overnight basis 184 
but only between 2 and 4 per 10,000 patient years for daily-wear patients. Major studies of the 185 
incidence of microbial keratitis associated with soft c ntact lenses are summarized in Table 1.59-186 
66 Regardless of the incidence, 15% or fewer of cases of microbial keratitis result in vision loss. 187 










With respect to soft contact lenses for myopia control, hree important variables influence the 190 
risk of corneal infiltrative events and microbial keratitis: storage, material, and patient age. First, 191 
many contact lenses designed for myopia control, thug  not all, are prescribed using a daily 192 
disposable replacement schedule.23 The benefits of eliminating contact lens storage as a risk 193 
factor cannot be understated. For example, Stapleton t al. found that the risk of moderate and 194 
severe microbial keratitis in daily wear contact lens users was increased 6.4 times by poor storage 195 
case hygiene and 5.4 times by infrequent storage cas replacement.67 The authors note the 196 
previously-reported associations between solution type and more severe disease for 197 
Acanthamoeba and Fusarium keratitis.68-70 Again, these risks can be substantially reduced with198 
daily disposable lenses. Second, contact lens material can also affect the risk for corneal 199 
infiltrative events. Over the past 20 years there has been a shift from traditional hydrogel 200 
materials towards silicone hydrogel materials which provide higher oxygen transmission.71 201 
Silicone hydrogels may increase the risk of corneal infiltrative events, but the broad benefits of 202 
these lenses outweigh this risk for many patients.72  203 
 204 
Third, age is a significant, but non-linear risk factor for contact lens-related adverse events. A 205 
retrospective, observational study evaluated the risk factors that interrupt soft contact lens wear 206 
among children, teenagers, and young adults.57 The authors reported 187 corneal infiltrative 207 
events in 3,549 patients for 14,305 visits observing 4,663 soft contact lens years including an 208 
average of 20 months of soft contact lens wear in 1,054 patients under the age of 18 years. The 209 
corneal infiltrative events included 8 cases of microbial keratitis, 110 of infiltrative keratitis, 41 210 
contact lens peripheral ulcers (CLPUs), 14 contact lens-induced acute red eye (CLARE) with 211 









nonlinear fashion up to age 21 and then decreased, with the peak years at risk from age 15 to 25 213 
years.  214 
 215 
Figure 1 replots the published data on corneal infiltrat ve events in terms of incidence (cases per 216 
10,000 patient years of wear).57 The figure demonstrates the marked lower rate of corneal 217 
infiltrative events in patients 8 to 12 years old (97 per 10,000 patient years, 95% CI, 31–235) 218 
than in patients 13 to 17 years old (335 per 10,000 patient years, 95% CI, 248–443). The 219 
incidence of microbial keratitis per 10,000 patient years varied dramatically with age group: 0 220 
(95% CI, 0–70) in 8- to 12-year olds, 15 (95% CI, 2–48) in the 13- to 17-year olds, 33 (95% CI, 221 
12–73) in the 18- to 25-year olds, and 7 (95% CI, 0.4–37) in the 26- to 33-year olds. 222 
 223 
The low rate of corneal infiltrative events in patients 8 to 12 years old from the above 224 
retrospective study of soft contact lens wear is supported by prospective studies. Bullimore 225 
reviewed data from nine prospective studies representing 1,800 patient years of wear in 7- to 19-226 
year-olds.73 The majority of the studies were at least one year in duration, fit children as young 227 
as 8 years, and represented over 150 patient years.23, 74-82 Pooling data across the nine studies, 14 228 
corneal infiltrative events were reported representing an incidence of 78 per 10,000 patient years 229 
(95% CI, 44–127). None of the studies reported any cases of microbial keratitis, giving a 95% CI 230 
of 0 to 21 per 10,000 patient years. A subsequent retrospective review of over 800 patient years 231 
of wear in children also found no cases of microbial keratitis,83 although a recent clinical trial of 232 










In summary, the incidence of corneal infiltrative events and microbial keratitis in children 12 235 
years and younger—in whom myopia control is likely to be initiated—is no higher than that 236 
observed in adults and may be lower.85, 86 The peak complication rate at 18-25 years suggests 237 
that behavioral and lifestyle factors may have a significant influence.87 For 8–12-year-olds, 238 
parents are more likely to be involved in lens care. It is also possible that young children wearing 239 
contact lenses are a pre-selected group, because they are likely to wear them responsibly. If 240 
contact lenses were worn by a higher proportion, the low complication rate could conceivably 241 
increase.  242 
 243 
 244 
Overnight Orthokeratology 245 
While the incidence of adverse events associated with soft contact lenses is well established, data 246 
for overnight orthokeratology are scarce. Even in large-scale epidemiological studies, where all 247 
lens types were considered, no cases of microbial keratitis in orthokeratology wearers are 248 
reported.65 Of course, this reflects the relatively small proportion of patients wearing this 249 
particular modality, rather than a low level of risk. Globally, orthokeratology represented 28% of 250 
all rigid contact lenses prescribed among minors betwe n 2005 to 2009.88 In the US, all rigid 251 
lenses account for around 10% of all contact lenses while patients 15 years and under account for 252 
only 11% of lens fits.71 Recent data suggest a steady, but small, increase in orthokeratology 253 
fitting through 2017, but only represents around 1% of all contact lens fits, with large 254 
geographical variations.89 Studies of the incidence of microbial keratitis asociated with contact 255 
lenses typically accrue cases from hospitals and other tertiary care settings and are unlikely to 256 
identify cases associated with overnight orthokeratology due to limited exposure, rather than the 257 









with overnight orthokeratology began to appear in the literature. The first 50 published cases 259 
were summarized in a 2005 paper90 and updated with total of 123 cases two years later.91 260 
 261 
In 2008, the American Academy of Ophthalmology published an Ophthalmic Technology 262 
Assessment for on the Safety of Overnight Orthokeratology for Myopia.28 The main source of 263 
adverse events was 38 case reports or noncomparative case series, representing more than 100 264 
cases of infectious keratitis. The report was unable, however, to identify the incidence of 265 
complications associated with overnight orthokeratology, nor the risk factors for various 266 
complications.  267 
 268 
The only comprehensive estimate of the incidence of microbial keratitis associated with 269 
overnight orthokeratology comes from a retrospectiv study, mandated and approved by the US 270 
Food and Drug Administration (FDA).92 Two hundred randomly selected practitioners, stratified 271 
by company and number of lens orders were asked to provide details on fitting date, and patient 272 
age at fitting, and follow-up duration for up to 50 randomly-selected lens orders. The 273 
practitioners were also asked to provide comprehensiv  information on any of these patients 274 
experiencing an episode of painful red eye that requi d a visit to a practitioner’s office. Patients 275 
treated by another practitioner or with less than twelve months of documented follow-up were 276 
mailed a questionnaire regarding months of lens wear, any adverse events and the name and 277 
address of the treating practitioner. Data were submitted by 86 practitioners on 1494 unique 278 
patients. Limiting the sample to at least three months of wear from 2005 onwards resulted in 279 
1,317 patients (49% adults 51% children) representing 2,599 patient years of wear. Of the 50 280 








in children. Of these cases, two were judged to be microbial keratitis by a five-person masked, 282 
expert review panel and neither resulted in any long-term loss of visual acuity. The overall 283 
incidence of microbial keratitis was 7.7 per 10,000 patient years (95% CI, 0.9–27.8). Both cases 284 
occurred in children giving an incidence of 14 per 10,000 patient years (95% CI, 1.7–50.4).92  285 
 286 
In summary, the incidence of microbial keratitis in children wearing overnight orthokeratology is 287 
similar to that reported for other overnight modalities in adults, notably extended wear of soft 288 
contact lenses (see Table 1). 289 
 290 
Modelling Risk of Vision Loss Associated with Myopia Treatment  291 
Given the above evidence, the risk of vision loss with spectacle lenses and atropine are 292 
considered negligible, and it is assumed that the majority of risk associated with myopia control 293 
will occur with contact lenses. The incidence of microbial keratitis varies with contact lens wear 294 
and all available estimates have some uncertainty as indicated by the breadth of the confidence 295 
intervals. Overnight orthokeratology in children carries a risk similar to other overnight 296 
modalities with the only estimate being 14 per 10,00  patient years (95% CI, 1.7–50).92 297 
Conversely, daily soft lens wear in children appears to be at least as safe as in adults; daily 298 
disposable lenses may further mitigate the risk.65 Thus, in evaluating vision loss associated with 299 
contact lens wear, a range of incidence should be considered. 300 
 301 
The above summary of the risks associated with myopia control expresses the data in terms of 302 
incidence. These data must be interpreted in terms of years of visual impairment associated with 303 









• 15% of all cases of microbial keratitis result in visual impairment (two lines of visual 305 
acuity or more) as this is the most conservative estimate.65 306 
• Each myopia control patient is exposed to 5 years of contact lens wear during the period 307 
of myopia control and the risk is constant over this time. Five years was chosen so that 1-308 
diopter of control could be reasonably anticipated.93 309 
• Any serious adverse event occurs during this five year period of wear, at a mean age of 310 
12 years. 311 
• Mean life expectancy is 82 years (https://www.mortality.org), so each adverse event 312 
causing immediate vision impairment results in 70 years lived with this vision 313 
impairment. 314 
 315 
Table 2 displays the years of vision loss for three levels of risk, expressed as annual incidence 316 
per 10,000 patients. The incidence values are intended to span the range reported in the literature 317 
from daily wear (1 per 10,000) to overnight wear (25 per 10,000).65 For example, the incidence 318 
of microbial keratitis with daily-disposable soft lenses could be assumed to be 1 per 10,000 319 
patient years of wear.65 The incidence of vision loss due to microbial keratitis is then estimated 320 
to be 0.15 per 10,000 patient years of wear, but five years of exposure would result in a 321 
cumulative incidence of vision loss of 0.75 per 10,00  patients (= 5 × 0.15). Finally, this vision 322 
loss is experienced for 70 years yielding a value of 53 years of vision loss per 10,000 patients (= 323 
70 × 0.75). The years of vision loss are proportionately higher for incidence values of 5 and 25 324 
per 10,000 patient years, the latter representing the upper limits for overnight orthokeratology. 325 
The effect of increasing exposure is easily calculated, e.g., for 10 years of exposure the 326 








for five years of exposure. Likewise, using an incidence of 50—the upper 95% limit for 328 
overnight orthokeratology in children92—the values in the final column would be doubled. 329 
 330 
The NNH for one and five years of visual impairment are also shown in Table 2. For example, 331 
38 patients would have to wear contact lenses with a medium risk of microbial keratitis 332 
(incidence = 5 per 10,000 patient years) for five years to result in one year of visual impairment. 333 
Likewise, 190 patients would have to wear them to result in five years of visual impairment.  334 
 335 
The Potential Benefits of Myopia Control 336 
Bullimore and Brennan recently summarized the benefits o  lowering levels of myopia.94 These 337 
include better uncorrected and corrected visual acuity, improved vision-related quality of life, 338 
and reduced dependence on correction. Likewise, a myope is likely to consider refractive surgery 339 
to correct their refractive error once they reach adulthood. In this regard, the lower the level of 340 
myopia, the higher the likelihood of minimal residual refractive error, leading to better 341 
postoperative uncorrected visual acuity and fewer scondary surgical enhancements. 342 
Furthermore, postoperative visual quality is poorer in patients with higher levels of preoperative 343 
myopia.95 Finally, higher myopia, thinner corneas, or both, can make them poor candidates for 344 
LASIK due to the increased risk for postoperative corneal ectasia96 and alternative procedures 345 
may be needed. In spite of these visual and refractive benefits of lower levels of myopia, the 346 
greatest benefit of lower levels of myopia is a reduced risk of blinding eye disease. The 347 
following sections briefly review the association between level of myopia and myopic 348 
maculopathy, cataract, retinal detachment and glaucoma. The reader is also referred to the recent 349 










Myopia and the Risk of Myopic Maculopathy 352 
There have been a number of large population-based stu ies of the prevalence of myopic 353 
maculopathy in older patients. Bullimore and Brennan94 summarized data from five that present 354 
the prevalence as a function of level of myopia in tabular or graphical form.97-101 Figure 2A 355 
shows the prevalence of myopic maculopathy as a function of degree of myopia for these five 356 
studies. Data are taken directly from each publication, digitizing figures to extract values when 357 
necessary.99, 102 Where prevalence was presented with data for ranges of myopia, the midpoint of 358 
each range was used. The highest level of myopia was often defined without an upper limit, so 359 
these data are not shown. In all studies, the prevalence of myopic maculopathy increases 360 
exponentially at higher levels of myopia. Figure 2B replots the prevalence of myopic 361 
maculopathy on a logarithmic scale. This results in an apparent linear relationship, with all 362 
studies showing a similar trajectory.  363 
 364 
Since publication of the above data, four more repots f the relation between myopia level and 365 
the prevalence of myopic maculopathy have been published,102-105 plus a fifth that does not 366 
contain sufficient categories.106 All available studies are summarized in Table 3 and represent 367 
data from over 10,000 myopes. The definition of myopia varies among studies, with two limited 368 
to high myopia. Likewise, the definition of myopic maculopathy varies slightly among studies 369 
with data for “macular complications” used from one.105 Linear regression was performed on 370 
each dataset and the results displayed in Table 3. The slope of log(prevalence) per diopter ranges 371 
from 0.095 to 0.271. Taking the antilog of these slopes gives the ratio of prevalence to diopter—372 









of myopia increases the prevalence of myopic maculopathy by 58%. Restated, controlling 374 
myopia progression such that a patient’s refractive error is lower by 1 D should reduce the 375 
likelihood of them developing myopic maculopathy by 37% (= 1 – 1/1.58). Furthermore, given 376 
the apparent constant slope of the data in Figure 2B, this treatment benefit is constant across a 377 
range of myopia severities. Thus, while the overall risk of myopic maculopathy is higher in a –6 378 
D myope than in a –3 D myope, slowing progression by 1 D during childhood should lower the 379 
risk by 37% in both. 380 
 381 
Myopia and the Risk of Other Ophthalmic Diseases 382 
Cataract 383 
Myopia is associated with other eye diseases. With respect to cataract, the association between 384 
myopia and posterior subcapsular (PSC) cataract is the most robust.107 A few studies have 385 
reported the prevalence of PSC at different degrees of myopia (Table 4).108-111 The same 386 
methodology as described in the previous section was used to determine the relation. The slope 387 
of log(prevalence) per diopter ranges from 0.017 to 0.103. Converting to a ratio of prevalence to 388 
diopters of myopia shows a range of 1.02x to 1.40x with a crude average of 1.21x. Thus, each 389 
diopter of myopia increases the prevalence of PSC cataract by 21%. While not directly 390 
comparable, Pan et al. reported that each diopter of my pia increases the odds of PSC cataract by 391 
1.14x in a sample of 5,474 Singaporean Malays.108 For cortical cataract, three of the studies in 392 
Table 4 show ratios of prevalence to diopter between 0.96x and 1.01x while one shows a ratio of 393 
1.16x.111 These same four studies show no relation between degree of myopia and nuclear 394 
cataract. The ratio of prevalence to diopters of myopia ranges from 0.95x to 0.99x with a crude 395 








myopia and nuclear cataract.107 Unfortunately, this relation is confounded by the myopic shift 397 
associated with nuclear cataract. Studies that have measured the ocular components find that 398 
nuclear cataract is associated with myopia, but not with axial length or its surrogates.107, 108, 112 399 
 400 
Retinal Detachment 401 
The association between retinal detachment and myopia is well established. While the global 402 
incidence of retinal detachment has been estimated  0.01% per year,113 three case-control 403 
studies allow quantification of the relation between myopia level and incidence of retinal 404 
detachment (Table 5).114-116 Other studies are listed that have based estimates of the relation on 405 
their cases of retinal detachment and published estimates of the distribution of refractive error.10, 406 
117, 118 The data from the most recent study119 were combined with recent estimates of myopia 407 
prevalence in the United Kingdom120 to derive the relation. The slope of log(incidence) p r 408 
diopter ranges from 0.096 to 0.173. Converting to a ratio of incidence to diopters of myopia 409 
shows a range of 1.15x to 1.49x with a crude average of 1.30x. Thus, each diopter of myopia 410 
increases the incidence of retinal detachment by 30%. 411 
 412 
Glaucoma 413 
Individuals with myopia have around twice the risk of developing open angle glaucoma 414 
compared with those without myopia. A meta-analysis of eight large studies estimated odds 415 
ratios of 2.46 (95% CI, 1.93–3.15) and 1.77 (95% CI, 1.41–2.23) for myopia above and below –3 416 
D, respectively.121 Table 6 summarizes data from five studies that present data on prevalence of 417 
open angle glaucoma for three or more levels of myopia.122-127 The slope of log(prevalence) per 418 









shows a range of 1.09x to 1.39x with a crude average of 1.20x. Thus, each diopter of myopia 420 
increases the prevalence of open angle glaucoma by 20%. Longer axial length is independently 421 
associated with an increased prevalence of open angle glaucoma.128, 129 Kuzin et al. estimated 422 
that each millimeter longer axial length was associated with a 26% higher prevalence.129 While 423 
the association between degree of myopia and prevalence of open angle glaucoma appears 424 
robust, there appears to be little or no relationship between myopia and rate of progression of 425 
glaucoma,130, 131 although higher myopes may have more severe disease and present diagnostic 426 
challenges.  427 
 428 
Myopia and the Risk of Visual Impairment 429 
Myopic maculopathy is associated with poorer visual acuity.97, 102 Vongphanit et al. reported that 430 
39% of 67 eyes with myopic maculopathy had visual impairment, based on a definition of 20/40 431 
or worse.97 Wong et al. reported that among 119 study participants identified as having myopic 432 
maculopathy, 26 (21.8%) had visual impairment in at least one eye, based on the same 433 
criterion.102 Finally, Gao et al. report that visual impairment was present in 10 participants 434 
(17.5%) based on the better eye, and using the critrion of worse than 20/60.99 While most of 435 
these studies, and the others in Table 3, precede the international photographic classification and 436 
grading system for myopic maculopathy,132 the criteria used to define myopic maculopathy are 437 
broadly similar: Category 2 (diffuse chorioretinal atrophy), Category 3 (patchy chorioretinal 438 
atrophy), Category 4: (macular atrophy) or one of the ‘‘plus’’ features: lacquer cracks, myopic 439 
choroidal neovascularization, and Fuchs spot. Category 1 (tessellated fundus) is not usually 440 
considered to represent myopic maculopathy as it is not associated with vision loss. The risk of 441 










Of course, any increase in the risk of visual impairment associated with myopia will be due to a 444 
range of diseases including myopic maculopathy. Given that multiple myopia-associated diseases 445 
can lead to visual impairment, the relevant parameter is the cumulative risk of all myopia 446 
associated pathologies. A few studies report visual impairment from all causes as a function of 447 
level of myopia.98, 105, 133, 134 Among these, Tideman et al. published the most comprehensive 448 
data on visual impairment and myopia, analyzing data from 15,404 adults (mean age 61±11 449 
years) in whom refractive error and visual acuity had been measured.134 In their Figure 2, they 450 
plot the cumulative risk of visual impairment as a function of age for five levels of myopia for a 451 
criterion of 20/67 (0.3 decimal acuity). Their graph was digitized, and the cumulative risk of 452 
visual impairment is replotted as a function of myopia level for five ages in Figure 3. The 453 
midpoint of each refractive error range was used an  value of –16 D chosen for the highest 454 
range. The data show a clear exponential trend at all ages, a feature that is emphasized by 455 
plotting them on a logarithmic scale. On the logarithmic scale, all ages follow a similar, near 456 
parallel trajectory. The best-fit slopes of these lines (not shown) range from 1.24 to 1.31x 457 
indicating that the cumulative risk of visual impairment increases by between 24 and 31% per 458 
diopter of myopia across a broad age range. 459 
  460 
From the values in Figure 3, the odds of visual impairment were calculated using a reference 461 
prevalence of 1.26%. This reference was calculated from the distribution of visual acuity among 462 
the four population-based cohorts used by Tideman et l., excluding the case-control study (their 463 
Table 1).134 Figure 4 shows the log10odds ratio of visual impairment as a function of age for five 464 
levels of myopia. Multiple linear regression was used to estimate log10odds ratio as a function of 465 









Log10Odds Ratio for Visual Impairment = 0.057Age – 0.122Rx – 4.03 467 
Thus:  468 
Cumulative Odds of Visual Impairment = 10(0.057Age – 0.122Rx – 4.03) 469 
Note that the coefficients show that the impact of one diopter of myopia is around twice that of 470 
one year of aging.  471 
 472 
Using this equation, the age-related cumulative risk of visual impairment can be modeled for 473 
different myopia levels. Figure 5 shows the cumulative risk of visual impairment as a function of 474 
age for seven levels of myopia and two different definitions of visual impairment. On the left is 475 
the model for the criterion for visual impairment used in the original data134 (worse than 20/67 or 476 
6/20) which is similar to the WHO’s ICD-11 definition of moderate visual impairment (worse 477 
than 20/60 or 6/18). The model on the right is for the US definition of visual impairment (worse 478 
than 20/40) which is also the WHO’s ICD-11 definition of mild visual impairment. These were 479 
calculated using the above equations for the odds of visual impairment but using an overall 480 
prevalence of 3.63%. This value was again calculated from the visual acuity distribution among 481 
the four population-based cohorts used by Tideman et l., excluding the case-control study (their 482 
Table 1).134 As would be expected both sets of curves follow a sigmoidal pattern. 483 
  484 
In order to further assess the impact of age and myopia on the visual impairment for individuals 485 
and the population, the above functions were combined with life expectancy data for the US 486 
population (https://www.mortality.org) to estimate the number of visually impaired persons per 487 
10,000 births as a function of age and myopia. A simple combination of the functions results is a 488 
series of asymmetric bell curves shown in Figure 6. The peak of the distribution shifts from 86 489 









year for each additional diopter of myopia up to –15 D (not shown). The presence of an earlier 491 
peak in higher myopes than in lower myopes reflects the earlier onset of myopia-related retinal 492 
complications105 than conditions where myopia is not a risk factor and may be protective, i.e., 493 
AMD and diabetic retinopathy.125 Beyond the peak, the influence of mortality outweighs the 494 
increased risk of visual impairment, resulting in a steadily decreasing probability of living with 495 
visual impairment. 496 
 497 
The mean number of years of visual impairment experienced by a patient over their lifetime may 498 
be estimated by simply integrating the area under each curve. For example, a –3 D myope will 499 
experience an average of 4.42 years of visual impair ent (US definition and WHO definition of 500 
moderate visual impairment), whereas a –8 D myope will experience 9.56 years of visual 501 
impairment. These data are summarized in Table 7. Furthermore, the benefit of slowing myopia 502 
progression by one diopter of myopia can be calculated as the difference in years of visual 503 
impairment (Table 7). Controlling myopia such that a patient destined to be a –3 D myope 504 
instead ends up as a –2 D myope should prevent an average of 0.84 years of visual impairment 505 
(= 5.25 – 4.42). Likewise, one diopter of myopia contr l such that, ultimately, a –8 D myope is 506 
instead a –7 D myope would save 1.22 years of visual mpairment (= 9.56 – 8.35).  507 
 508 
Table 7 also shows the number of patients needed to treat (NNT)—the number slowed by one 509 
diopter—to prevent five years of visual impairment. For –3 D of myopia the NNT is 6.75, while 510 
for –8 D of myopia the NNT is 4.11. Finally, the reduction in myopia needed to prevent one year 511 
of visual impairment in a given patient can be estima ed. For –3 D of myopia a 1.38-D reduction 512 









context, the NNT for preventing one nonfatal heart attack in asymptomatic adults 40 years or 514 
older with statin medications is 217, and the NNT to prevent one nonfatal stroke, 313.135 515 
 516 
The corresponding data for the WHO definition of moderate visual impairment are shown in 517 
Table 8. Both the mean years of visual impairment and the years of visual impairment prevented 518 
by a 1 diopter reduction in myopia are smaller than for the US definition. Likewise, the NNT to 519 
prevent one year of visual impairment and the reduction in myopia needed to prevent one year of 520 
visual impairment are higher. 521 
 522 
Comparing the Risks and Benefits of Myopia Control 523 
The above model shows the potential benefit of slowing myopia progression such that a patient 524 
ends up with one diopter less than their original refractive trajectory. Recent randomized clinical 525 
trials suggest that one diopter of myopia control is achievable given that a 0.73 D reduction in 526 
progression was achieved with three years of treatmnt with a daily-disposable soft contact lens 527 
incorporating a dual-focus optical design,23 a 0.71 D reduction with three years of executive 528 
bifocal spectacle wear,33 and a 0.82 D reduction with two years of 1% atropine therapy.46 While 529 
few studies have reported myopia control on patients beyond 3 years,136, 137 the above results 530 
suggest that one diopter is feasible, but would take up to five years of treatment.93 531 
 532 
The above model predicts that one diopter of myopia control can prevent between 0.74 and 1.22 533 
years (9 to 15 months) of visual impairment for myopia levels between –3 and –8 D. Referring 534 
back to the years of visual impairment that might be associated with five years of contact lens 535 
wear (Table 2), the range corresponding to the published range of incidence levels of microbial 536 









a range of 0.0053 to 0.1312 years per patient. Thisleads to the reasonable conclusion that the 538 
benefits of myopia control far outweigh the risks of the five years of contact lens wear required 539 
to achieve this one diopter of control. Another way to compare risk and benefit is using NNH 540 
and NNT. For the range of values in Table 2 the NNH for five years of visual impairment is 541 
between 38 and 945. In other words, even for the highest incidence of microbial keratitis (25 per 542 
10,000 years), 38 patients would need to be exposed t  in uce five years of visual impairment. In 543 
contrast, only 4.11 to 6.75 patients would need to have their ultimate myopia level reduced by 544 
one diopter to prevent five years of visual impairment. For the level of risk that might be 545 
expected for myopia control using daily disposable contact lenses, (1 per 10,000  years) the 546 
NNH outweighs the NNT by a ratio of 140 for a –3 D myope (=945/6.75) and 230 for a –8 D 547 
myope (=945/4.11). Thus, for therapies that carry low risk, the benefits are compelling, but for 548 
smaller amounts of myopia control, or higher levels of risk, the benefits are still meaningful. For 549 
example, slowing myopia by 0.50 D—equivalent to slowing axial elongation by 0.18 mm138—550 
would still lower the risk of myopic maculopathy by20% and, on average, prevent six months of 551 
visual impairment.  552 
 553 
This comparison reflects conservative estimates of the total treatment benefit from myopia 554 
control derived from current methods of management.93 The benefits would scale up if a greater 555 
level of myopia control could be achieved, especially for higher myopes. For example, the data 556 
in Table 7 can be used to calculate the benefit of 2-diopters of control in a patient destined to be 557 
a –7 D myope (8.35 – 6.19 = 2.16 years of visual impairment) or 3-diopters of slowing in a 558 











An important consideration is that values for visual impairment associated with myopia are for 562 
bilateral impairment (tables 7 and 8), whereas the estimates of vision loss associated with contact 563 
lens wear in Table 2 are monocular and correspond t rates based on two lines loss of visual 564 
acuity.65 Bilateral cases of contact lens-related microbial keratitis are rare. For example, among 565 
the 367 cases reported by Dart et al., only one was bil teral.66 Even in large case series of 566 
acanthamoeba keratitis bilateral infection occurs in only 5 of 183139 and 3 of 154 cases.140 567 
Furthermore, while some cases of vision loss due to contact lens-associated infections require 568 
corneal transplants, less severe cases might be ameliorat d with rigid contact lenses or 569 
phototherapeutic keratectomy.141, 142 In summary, the binocular visual impairment associated 570 
with contact lenses is far lower than the binocular visual impairment associated with each 571 
additional diopter of myopia. Of course, a patient who has reduced vision in one eye is then at 572 
greater risk of bilateral visual impairment throughout the rest of their life as a result of other 573 
causes143 and the loss of binocularity could impact future career choices and quality of life. 574 
 575 
Limitations of Model 576 
A number of assumptions are required to produce a model of risk/benefit from myopia control 577 
and the accuracy of such a model is dependent on the validity of these assumptions. Our model 578 
of visual impairment and myopia uses some interpolation regarding age as only data through 75 579 
years were available. It is possible that relation between myopia and visual impairment is 580 
different at older ages, for example, the prevalence of age-related macular degeneration is lower 581 
in myopes.125 The rising worldwide prevalence of myopia is leading to secular trends. A large 582 
population-based Japanese study reported that the age-adjusted prevalence of myopic 583 









retinal detachment in the Netherlands over a 7-year p riod that the authors attribute to myopia, 585 
although this is a small contributor to visual impairment.144 A similar increase was previously 586 
reported in Scotland.145 The inclusion of both age and myopia level in the model of visual 587 
impairment should make it relatively robust moving forward. 588 
 589 
The assessment of vision loss associated with contat lens wear assumes that the risk is constant 590 
over time and independent of refractive error. As demonstrated in Figure 1, the incidence of 591 
contact lens-related adverse events increases as children become teenagers,57 presumably due to 592 
engaging in behavior likely to increase the risk of adverse events.87 Likewise, higher myopes are 593 
more likely to engage in risky behavior related to their contact lenses.146, 147 A value of 15% for 594 
the proportion of cases of microbial keratitis was chosen, based on the two lines loss of visual 595 
acuity.64, 65 Other studies have reported rates of 4% for a criterion of 20/40 or worse66 and 5% 596 
based on 20/70 or worse.61 The calculations in Table 2 are all linear, so the eff ct of replacing 597 
0.15 with a different value is easily calculated. Our model of visual impairment associated with 598 
contact lens assumes that the design of the lens does n t play a role and that the increased risk is 599 
due to increased exposure. Intuitively, those additional years of wear would occur when the child 600 
is younger and their myopia relatively low. 601 
 602 
The current model assumes a fixed treatment effect with myopia control. While the efficacy of 603 
these technologies show a reduction in subsequent years of treatment,93 a more sophisticated 604 
model or simulation could explore variations in trea ment duration, treatment effect, or both. The 605 
model also uses data from only one paper reporting predominantly white Europeans, although a 606 









between myopia level and visual impairment.105 Both studies include all causes of visual 608 
impairment and thus account for age-related increases in AMD and the potentially protective 609 
effect of myopia. It will be important to extend these results to other populations as data become 610 
available, particularly Asians where the prevalence of myopia is higher. It should be noted that 611 
the prevalence of visual impairment in this Dutch population148 is lower than other comparable 612 
populations.149, 150  613 
 614 
Recent comprehensive reviews of the efficacy of myopia control are available,17, 93, 151 but long-615 
term data on myopia control and whether the benefits are sustained are scarce. Few published 616 
studies are longer than three years in duration. Of the 26 studies considered by Brennan et al., 617 
only four exceed two years and the majority of repots in the literature are one year in duration.93 618 
Likewise few studies demonstrate more than 1 D of treatment effect,136, 137, 152 and caution must 619 
be exercised when extrapolating the findings of shorter duration trials, as slowing of progression 620 
in the first year of treatment is greater than in subsequent years.93 Nonetheless, a recent report of 621 
the only FDA-approved myopia control device demonstrates a six-year 0.53 mm slowing of axial 622 
elongation, which in dioptric terms approaches 1.50 D.152  623 
 624 
The extent to which benefits are sustained once treatm nt is withdrawn is not settled. Dramatic 625 
post-treatment acceleration, or rebound, has been rported with 1% atropine, but does not seem 626 
to occur with spectacle35 or soft contact lens therapies.75, 153 Nonetheless, some level of rebound 627 
should be assumed until proven otherwise.93 The choice of treatment will be ultimately be 628 
determined by a discussion among practitioner, parent, and patient, but influenced by regional 629 










The use of NNT and their comparison with NNH is notbeyond reproach.154-156 NNTs vary with 632 
baseline or event rate and a NNT without the treatmn  period and follow-up period is difficult to 633 
interpret. For these reasons, a range of rates of visual impairment was explored, with care to 634 
specify the duration of treatment and calculate years living with any impairment. Comparisons 635 
between different outcomes, for example, risks of microbial keratitis in contact lens wear with 636 
risk of vision impairment due to increasing myopia could also be criticized.157 In contrast, the 637 
analyses express both NNH and NNT in a single metric—years of visual impairment. A further 638 
valid criticism of the presentation of NNH and NNT is the absence of confidence intervals. The 639 
naive approach to calculating a confidence interval for NNT is by inverting the limits for ARR, 640 
but this does not yield a valid interval. Our approach has been to explore a range of underlying 641 
assumptions and present data for a range of risks and benefits. Finally, the analysis assumes that 642 
all years of visual impairment are created equal, which may or not be valid. For example, visual 643 
impairment earlier in life may impact earning potential and comparing this with later-onset 644 
visual impairment where comorbidities may exist is a complex problem.158 645 
 646 
Finally, this is not a cost-benefit analysis and future work should consider the cost associated 647 
with myopia control, including those associated with adverse events, along the potential savings 648 
associated with any reduction in ocular morbidity. Nonetheless, some brief comment is 649 
warranted. First, there have been few attempts to etimate the costs of visual impairment. Frick et 650 
al.159 used Medical Expenditure Panel Survey data to estimate the effect of visual impairment 651 
with total medical expenditures, components of expenditures, days of informal care received 652 









States. The direct costs of visual impairment (individual excess medical expenditures) were 654 
estimated to be $1,037 (for 2004). Adjusted for 2021, this is $1,446. For indirect costs, Frick et 655 
al. assumed visual impairment corresponds to a loss of 0.05 quality-adjusted life years (QALYs) 656 
and use a “common but arbitrary value for a QALY in the US of $50,000” resulting in $2,500160 657 
Adjusted for 2020 gives $3,779. Frick et al. acknowledge that their estimate of the economic 658 
impact is limited, because it does not include productivity loss.159 Furthermore, all estimates can 659 
vary dramatically with the underlying assumptions. For example, other authors apply an upper 660 
limit of $100,000 per QALY and consider the differenc  between 20/20 and 20/40 to represent 661 
0.12 QALYs.158 662 
 663 
The costs associated with myopia control are also challenging to estimate. At the time of writing 664 
only one device or drug is FDA-approved for myopia control in the US and was only launched in 665 
the past year, although it has been available in other countries for some years. Analyses would 666 
need to include costs of drugs or lenses, but these are incremental as the child will already be 667 
wearing spectacles or contact lenses. The cost of additional office visits and measurements, 668 
including axial length will also need to be incorporated. All these costs will vary across 669 
countries.  670 
 671 
The cost to families of myopia control when that trea ment is not generally covered by vision or 672 
medical insurance may mean that the prevention or slowing of myopia to reduce the risk of 673 
visual impairment later in life may be at the expense of other medical conditions, such as oral 674 
care.161 This can potentially exacerbate health disparities in underserved communities as 675 









supplemental material in the recently published repo t of the American Academy of 677 
Ophthalmology Task Force on Myopia,163 includes a number of goals, including “Encouraging 678 
government and commercial insurers to cover myopia control as part of their medical and vision 679 
benefits would further expand the interventions avail ble to clinicians and might allay future 680 
vision loss and costs associated with higher degrees of myopia. Health disparities in myopic 681 
minority children in the United States are likely to be amplified unless insurance coverage for 682 
myopia treatments is expanded.” We feel that all stkeholders should consider this issue.  683 
 684 
Finally, those at the greatest risk of developing maculopathy and visual impairment are those 685 
with higher levels of myopia.134 Likewise, our model shows that the greatest individual 686 
reductions in visual impairment from myopia control are accrued in higher myopes. Given the 687 
strong relation between age of onset and ultimate sev rity of myopia,2, 4 it is most important to 688 
direct efforts at those children who develop myopia rel tively early. As Brennan et al.93 recently 689 
stated, “Because of the risks of complications later in life and our current inability to predict with 690 
great accuracy those who go on to higher degrees of my pia, this leads us to recommend that all 691 
young myopes (say 12 years of age and below) deserv to be treated.” 692 
 693 
One question that is currently unresolvable, is whether the observed associations of refractive 694 
error and ocular disease are directly causal and whether a reduction in myopia with treatment 695 
will reduce the associated risks. Due to the 40 or m e-year delay between myopia treatment and 696 
the increased risk of vision loss, this is a challenging question to address. One suggestion that 697 
there is a causal relationship is the increasing prevalence of myopic maculopathy associated 698 









severity such as China where myopic maculopathy has risen to become the leading cause of 700 
vision impairment.14, 164 Myopic maculopathy is also the leading cause of uncorrectable visual 701 
impairment among Chinese Americans.165  702 
 703 
Conclusion 704 
In summary, we have reviewed the risks associated with various myopia control therapies, 705 
particularly contact lenses, and the predicted visual loss from five years for therapy. We have 706 
examined the increased risk of ocular disease associated with increasing levels of myopia and, 707 
more importantly, the relation between visual impairment and myopia level. Finally, we compare 708 
the potential benefits of reducing a patient’s ultimate level of myopia by one diopter. Our model 709 
suggests the potential benefits of myopia control outweigh the risks: the number needed to treat 710 
to prevent 5 years of visual impairment is between 4.1 and 6.8 while fewer than 1 in 38 will 711 
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Figure 1.  
The incidence of different inflammatory events involving the cornea and iris as a function of 
patient age. Data are replotted from Chalmers et al.57 CLARE = contact lens-induced acute 
red eye, CLPU = contact lens peripheral ulcer.  
 
Figure 2.  
The prevalence of myopic maculopathy plotted with both linear (left) and logarithmic (right) 
scales, replotted from Bullimore and Brennan94. The logarithmic scale emphasizes the similar 
trajectory of each data set, the additional risk associated with each diopter.  
 
Figure 3.  
The cumulative risk of visual impairment as a function of level of myopia for five ages. The left 
panel uses a linear scale, while the right panel uss a logarithmic scale. Data are from Figure 2 of 
Tideman et al.134 
 
Figure 4.  
The log10 odds of visual impairment as a function of level of myopia for five ages plotted a 
logarithmic scale. Based on data from Tideman et al.134 
 
Figure 5.  
Model of visual impairment as a function of age (years) for different levels of myopia and two 
different definitions of visual impairment. The left panel is 134 (worse than 20/67 or 6/20) which 
is similar to the WHO’s ICD-11 definition of moderate visual impairment (worse than 20/60 or 
6/18), while the right panel is for the US definition (worse than 20/40) which is also the WHO’s 
ICD-11 definition of mild visual impairment. 
 
Figure 6.  
By combining the risk of visual impairment as a function of age for different levels of myopia 









determined. The mean number of years of visual impair ent experienced by a patient over their 













Table 1. Incidence of microbial keratitis in adults associated with daily and regular overnight wear of soft 
contact lenses. Two studies distinguish between hydrogel and silicone hydrogel soft contact lenses, so both 
values are shown.63, 65 When available, the percentage of cases leading to visi n loss is shown. Vision loss 
is defined as two lines loss of visual acuity64, 65, 20/40 or worse66, or 20/70 or worse.61 
 
Country of Study Year Number 
of Cases 
Incidence of microbial keratitis 
(per 10,000 years of wear) Percentage of Cases 
Leading to Vision Loss 
Daily Wear Overnight Wear 
United States59 1989 137 4.1 20.9 — 
Scotland60 1999 20 2.4 — — 
Netherlands61 1999 92 3.5 20.0 5% 
Hong Kong62 2002 59 3.1 9.3  
England63, 64 2005 38 6.4/0.0 96.4/19.8 0% 
Australia65 2008 244 1.9/11.9 19.5/25.4 15% 










Table 2. Vision loss associated with three levels of risk of microbial keratitis (MK). It is assumed that 15% of cases 
of microbial keratitis result in vision loss, that exposure is five years, and that any vision loss is experienced for 70 
years after the event. All values are per 10,000 patients. 
 
Variable Multiplier Low Risk Medium Risk High Risk 
Annual incidence of MK  1 5 25 
Annual incidence of vision loss × 15% 0.15 0.75 3.75 
Accumulated incidence of vision loss × 5 years 0.75 3.75 18.75 
Years of vision loss accrued × 70 years 53 263 1,312 
NNH for one year of vision loss 10,000/ 
years vision loss 
189 38 7.5 
NNH for five years of vision loss 5 × 10,000/ 
years vision loss 
945 190 38 





































(< –1 D) 







(< –0.5 D) 





(≤ –0.5 D) 







(< –0.5 D) 







(≤ 0 D) 
0.199 1.58x +58% –37% 
Singapore102 




(≤ –0.5 D) 
0.095 1.24x +24% –20% 
Zhongshan, 
China103 




(≤ –6 D) 
0.230 1.70x +70% –41% 
France105 60+  (≤ –0.5 D) 0.143 1.39x +39% –28% 
Germany104 




(≤ –6 D) 









Table 4. Summary of studies of the relation between d gree of myopia and the prevalence of posterior 


















Dam, US111  
43 to 84 
(61±11) 4,470 1,149 0.145 1.40x +40% –28% 
Singapore 
Chinese110 
40 to 79 1,029 340 0.009 1.02x +2% –2% 
Salisbury, 
US109 




736 eyes 0.103 1.27x +27% –21% 
Singapore 
Indian108 
40 to 84 
(59±10) 











Table 5. Summary of studies of the relation between d gree of myopia and the incidence of retinal 
detachment.  
 













Japan114 1,166 11,671 0.113 1.30x +30% –23% 
EDCCS, US115 253 1,138 0.110 1.29x +29% –22% 
China116 61 61 0.059 1.15 +15% –13% 
Switzerland118 195 — 0.096 1.25x +25% –20% 
England10 452 — 0.173 1.49x +49% –33% 
Iowa, US117  172 — 0.156 1.43x +43% –30% 










Table 6. Summary of studies of the relation between d gree of myopia and the prevalence of primary open 


















40 to 90 
(51) 5150 — 0.032 1.08x +8% –7% 
Beijing123 
40 to 101 
(56±10) 
4,319 978 0.066 1.16x +16% –14% 
NHANES, 
US124 
40 and older 5,277 1,241 0.053 1.13x +13% –12% 
Singapore 
Indian125 
40 to 84 
(59±10) 
5,768 1,498 0.144 1.39x +39% –28% 
South 
Korea126 
40 and older 13,433 2,986 0.082 1.21x +21% –17% 
Kaiser, 
US127 
35 and older 
(58±12) 










Table 7. Mean lifetime years of visual impairment (VI) as  function of level of myopia using the US definition of 
20/40, which is WHO definition of mild visual impairment. Also shown are mean years of visual impairment 
prevented by a 1 D reduction in a patient’s ultimate level of myopia, the number of patients needed to treat (NNT) in 





Mean Years of 
VI per Patient 
Years of VI 
Prevented by 1 
Diopter Reduction 
Number Needed to 
Treat to Prevent  
5 years of VI 
Reduction Needed 
to Prevent One 
Year of VI (D) 
–3 4.42 0.74 6.75 1.38 
–4 5.25 0.84 5.97 1.22 
–5 6.19 0.93 5.35 1.07 
–6 7.22 1.03 4.85 0.97 
–7 8.35 1.13 4.44 0.88 










Table 8. Mean lifetime years of visual impairment (VI) as  function of level of myopia using the WHO definition 
of moderate visual impairment: 20/60. Also shown are mean years of visual impairment prevented by a 1 D
reduction in a patient’s ultimate level of myopia, the number of patients needed to treat (NNT) in order to prevent 5 




Mean Years of 
VI per Patient 
Years of VI 
Prevented by 1 
Diopter Reduction 
Number Needed to 
Treat to Prevent  
5 years of VI 
Reduction Needed 
to Prevent One 
Year of VI (D) 
–3 2.06 0.41 12.24 — 
–4 2.55 0.49 10.29 2.33 
–5 3.12 0.57 8.77 1.88 
–6 3.78 0.66 7.58 1.58 
–7 4.53 0.75 6.63 1.36 




















































We consider whether the potential benefits of slowing myopic progression by one diopter justify 
the potential risks associated with treatments, based on published data on risks and the relation 
between visual impairment and myopia. 
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